The North American-AIDS Cohort Collaboration on Research and Design (NA-ACCORD) began in 2006 as the representative of Region 1 of the leDEA initiative. The 22 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV/AIDS cohorts within North America. Over 100 sites in the US and Canada contribute data collected from over 100,000 HIV-infected and 150,000 HIV-uninfected participants. During the last 4 years, we established a strong collaborative infrastructure that capitalizes on the talents and expertise of a multi-disciplinary group of investigators that span basic science, clinical research, epidemiology, data informatics and biostatistics. We have been highly productive in addressing our original Aims and expanding our scientific focus to several areas of contemporary importance in HIV in North America. Our collaboration is well-positioned to successfully answer the key questions in practice today. We have three broadly-defined aims for the next funding cycle:
Aim 1 : Determine the clinical epidemiology of HIV infection in North America, with a focus on aging and the incidence and determinants of non-AIDS co-morbidities.
Aim 2 : Provide unique data on current and evolving trends, outcomes and comparative effectiveness of treatment of HIV infection in North America, with a focus on the timing of presentation for HIV care and the initial use of ART, determinants of long-term viral suppression, immune recovery, and clinical disease progression, the impact of hepatitis C co-infection, and the development of resistance.
Aim 3 : Capitalize on our large sample size to quantify and identify factors associated with important rare events and support translational research. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to provide definitive answers to these issues of contemporary relevance in the U.S. and Canada. In addition, we will expand our collaboration with other leDEA regions to both inform future experience in resource-limited regions as the treatment of the epidemics mature, and to identify and understand differences in treatment, outcomes and prognostic factors that might inform future research and clinical care globally.

Public Health Relevance

The NA-ACCORD is the most comprehensive collaboration of HIV cohorts that exists within North America. Its large sample size, the comprehensiveness and quality of its data, combined with the expert use of state- of-the-art statistical methods will allow us to provide answers to critical questions of contemporary importance for the care of HIV-infected individuals in the U.S. and Canada.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069918-08
Application #
8512648
Study Section
Special Emphasis Panel (ZAI1-BB-A (M2))
Program Officer
Zimand, Lori B
Project Start
2006-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
8
Fiscal Year
2013
Total Cost
$1,904,692
Indirect Cost
$242,363
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903
Eyawo, Oghenowede; McGinnis, Kathleen A; Justice, Amy C et al. (2018) Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr 77:135-143
Oh, Eric J; Shepherd, Bryan E; Lumley, Thomas et al. (2018) Considerations for analysis of time-to-event outcomes measured with error: Bias and correction with SIMEX. Stat Med 37:1276-1289
Lesko, Catherine R; Jacobson, Lisa P; Althoff, Keri N et al. (2018) Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. Int J Epidemiol 47:654-668
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Lee, Jennifer S; Cole, Stephen R; Achenbach, Chad J et al. (2018) Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS One 13:e0197665

Showing the most recent 10 out of 160 publications